Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer

Pauls, Mehrnoosh; Chia, Stephen; LeVasseur, Nathalie

doi:10.3390/curroncol29070377

Cited by 13 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ongoing research on ADC drugs in combination with PARP, PD-L1 inhibitors, and other related drugs is also worth considering. 44 In addition, the proposal for low HER2 expression has expanded the indications for trastuzumab deruxtecan. With the positive conclusion of the DESTINY-Breast04 study, trastuzumab deruxtecan was approved by the US Food and Drug Administration for use in cases of low HER2 expression hormone receptor-negative populations.…”

Section: Discussionmentioning

confidence: 99%

Third-line Treatment for Metastatic Triple-negative Breast Cancer

Shi,

Li,

Wang

et al. 2023

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: Metastatic triple-negative breast cancer (mTNBC) is an invasive histologic subtype with a poor prognosis and rapid progression. Currently, there is no standard therapy for the third-line treatment of mTNBC. In this study, we conducted a network meta-analysis to compare regimens and determine treatment outcomes. Methods: We performed a systematic search of PubMed, EMBASE, the Cochrane Central Register of Controlled Bases, and the minutes of major conferences. Progression-free survival, overall survival, and objective response rate were analyzed through network meta-analysis using the R software (R Core Team). The efficacy of the treatment regimens was compared using hazard ratios, odds ratios, and 95% CIs. Results: We evaluated 15 randomized controlled trials involving 6,010 patients. Compared with the physician’s choice treatment, sacituzumab govitecan showed significant advantages in progression-free survival and overall survival, with hazard ratio values of 0.41 (95% CI: 0.32-0.52) and 0.48 (95% CI, 0.39-0.60). In terms of objective response rate, sacituzumab govitecan is the best-performing therapy (odds ratio: 10.82; 95% CI: 5.58-20.97). Adverse events among grades 3 to 5 adverse reactions, the incidence of neutropenia and leukopenia in each regimen was higher, whereas the incidence of fever, headache, hypertension, and rash was lower. Conclusion: Compared with the treatment of the physician’s choice, sacituzumab govitecan appears more efficacious and is the preferred third-line treatment for mTNBC.

show abstract

Section: Discussionmentioning

confidence: 99%

Third-line Treatment for Metastatic Triple-negative Breast Cancer

Shi,

Li,

Wang

et al. 2023

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Currently, the management of TNBC that is unresponsive to the current treatment approaches is still a main clinical challenge and for this reason it is important to develop novel therapeutic strategies [ 3 , 50 , 51 , 52 ]. In this study, we demonstrated that zein nanoparticles can be used as biocompatible carriers for the co-delivery of the BET inhibitor JQ1 and PTX, two molecules characterized by a strong lipophilic character [ 4 , 53 ].…”

Section: Discussionmentioning

confidence: 99%

Co-Encapsulation of Paclitaxel and JQ1 in Zein Nanoparticles as Potential Innovative Nanomedicine

et al. 2022

View full text Add to dashboard Cite

The manuscript describes the development of zein nanoparticles containing paclitaxel (PTX) and the bromo-and extra-terminal domain inhibitor (S)-tertbutyl2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate (JQ1) together with their cytotoxicity on triple-negative breast cancer cells. The rationale of this association is that of exploiting different types of cancer cells as targets in order to obtain increased pharmacological activity with respect to that exerted by the single agents. Zein, a protein found in the endosperm of corn, was used as a biomaterial to obtain multidrug carriers characterized by mean sizes of ˂200 nm, a low polydispersity index (0.1–0.2) and a negative surface charge. An entrapment efficiency of ~35% of both the drugs was obtained when 0.3 mg/mL of the active compounds were used during the nanoprecipitation procedure. No adverse phenomena such as sedimentation, macro-aggregation or flocculation occurred when the nanosystems were heated to 37 °C. The multidrug nanoformulation demonstrated significant in vitro cytototoxic activity against MDA-MB-157 and MDA-MB-231 cancer cells by MTT-test and adhesion assay which was stronger than that of the compounds encapsulated as single agents. The results evidence the potential application of zein nanoparticles containing PTX and JQ1 as a novel nanomedicine.

show abstract

“…There are several treatment schemes for early diagnosed TNBC that are based on anthracycline and taxane administration, but which cause numerous adverse effects (nausea, fatigue, gastrointestinal toxicity, myelosuppression, alopecia, hypothyroidism, hyperthyroidism, pneumonitis, skin reactions, adrenal insufficiency, peripheral neuropathy, neutropenia, pyrexia, anemia, thrombocytopenia, electrolyte abnormalities, infection, etc.) and do not lower the relapse rate [ 50 ].…”

Section: Molecular Characteristics Of Tnbcmentioning

confidence: 99%

Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy

Balahura

Dinescu

Costache

2023

IJMS

View full text Add to dashboard Cite

During the past decade, researchers have investigated the molecular mechanisms of breast cancer initiation and progression, especially triple-negative breast cancer (TNBC), in order to identify specific biomarkers that could serve as feasible targets for innovative therapeutic strategies development. TNBC is characterized by a dynamic and aggressive nature, due to the absence of estrogen, progesterone and human epidermal growth factor 2 receptors. TNBC progression is associated with the dysregulation of nucleotide-binding oligomerization domain-like receptor and pyrin domain-containing protein 3 (NLRP3) inflammasome, followed by the release of pro-inflammatory cytokines and caspase-1 dependent cell death, termed pyroptosis. The heterogeneity of the breast tumor microenvironment triggers the interest of non-coding RNAs’ involvement in NLRP3 inflammasome assembly, TNBC progression and metastasis. Non-coding RNAs are paramount regulators of carcinogenesis and inflammasome pathways, which could help in the development of efficient treatments. This review aims to highlight the contribution of non-coding RNAs that support inflammasome activation and TNBC progression, pointing up their potential for clinical applications as biomarkers for diagnosis and therapy.

show abstract

Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer

Cited by 13 publications

References 41 publications

Third-line Treatment for Metastatic Triple-negative Breast Cancer

Third-line Treatment for Metastatic Triple-negative Breast Cancer

Co-Encapsulation of Paclitaxel and JQ1 in Zein Nanoparticles as Potential Innovative Nanomedicine

Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy

Contact Info

Product

Resources

About